Drug Trial Radar · NCT07235059
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
Jan 21, 2028
Study completion Jan 21, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Conditions
- Chronic Kidney Disease
Interventions
OJR520Drug
Participants will receive OJR520 in different dose levels.
PlaceboOther
Participants will receive OJR520 matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: From Day 1 (Part A) until Day 71 (Part C)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Quotient Sciences Sea View
Miami, Florida · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.